Drugs of Misuse and Substance Use Disorders: Mechanisms, Overdose and Evidence-Based Treatment

Educational pharmacology review updated 10 November 2026. This material does not replace clinical evaluation, local licensing rules or patient-specific prescribing guidance.

Overview

Psychoactive substances can produce intoxication, tolerance, withdrawal and substance use disorders. Diagnosis considers impaired control, continued use despite harm and other clinical criteria—not exposure or physical dependence alone. Person-centred, non-stigmatizing language and timely treatment improve access to care [1–3].

Major substance classes and mechanisms

  • Opioids: morphine, heroin, fentanyl and others activate μ-opioid receptors (Gi/o), reducing neurotransmitter release and causing analgesia, euphoria, sedation and potentially fatal respiratory depression.
  • Stimulants: cocaine inhibits monoamine transporters; amphetamines promote catecholamine release and alter monoamine transport, increasing sympathetic activity.
  • Alcohol: affects GABAergic, glutamatergic and other signaling; severe withdrawal may cause seizures or delirium.
  • Benzodiazepines: positive allosteric modulators at GABA-A receptors, with greater respiratory risk when combined with opioids or alcohol.
  • Cannabinoids: THC is a partial agonist of cannabinoid receptors, especially CB1; CBD has distinct, complex actions and is not equivalent to THC.
  • Psychedelics/dissociatives: psilocin has prominent 5-HT2A agonism, whereas ketamine antagonizes NMDA receptors [1].

Opioid overdose and immediate response

Suspected opioid overdose with reduced responsiveness and slow or absent breathing is a medical emergency. Call emergency services, administer naloxone according to its product instructions, support breathing/CPR as appropriate and monitor for recurrent sedation because naloxone may wear off before the opioid. Additional naloxone doses may be necessary. Do not withhold naloxone because the exact substance is unknown [2].

Opioid use disorder treatments

Buprenorphine (partial μ agonist) and methadone (full μ agonist) are evidence-based first-line opioid agonist treatments that reduce mortality; naltrexone (antagonist) is an alternative for appropriately selected opioid-free patients. Withdrawal management or detoxification alone is not recommended because recurrence and overdose risks are substantial. Treatment initiation and continuation should involve clinicians knowledgeable about local regulations, drug interactions and overdose risks [2,3].

Other substance use disorders

Alcohol use disorder pharmacotherapies include naltrexone and acamprosate, with disulfiram reserved for selected supervised situations; liver/kidney function and concurrent opioids influence choice. Nicotine dependence treatments include nicotine replacement, varenicline and bupropion where appropriate. No medication is universally approved as a first-line pharmacotherapy for stimulant use disorder; contingency management and other behavioral interventions have evidence of benefit [1,3].

Clinical safety and counselling

Acute stimulant toxicity may cause hyperthermia, agitation, arrhythmia and seizures; benzodiazepine or alcohol withdrawal may require medically supervised treatment because of seizures and delirium risk. Combining opioids with benzodiazepines, alcohol or other sedatives substantially increases overdose risk. Offer take-home naloxone, infection prevention, psychosocial support, and continued care without making counseling a barrier to effective medication treatment [2,3].

References

  1. Brunton LL, Knollmann BC, editors. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 14th ed. McGraw Hill; 2023.
  2. Centers for Disease Control and Prevention. Opioid use disorder: treating. 2024 Apr 9. Available from: https://www.cdc.gov/overdose-prevention/hcp/clinical-care/opioid-use-disorder-treating.html
  3. National clinical practice guideline for opioid use disorder: 2024 update. CMAJ. 2024. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC11573384/
Medical & AI Disclaimer

The information provided on Sumathi Publications is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding any medical condition or treatment decision.

We strive to keep our content accurate and up to date; however, some content may be created or assisted using artificial intelligence (AI) and may contain errors or omissions. All information should be independently verified before use. Reliance on any content provided by Pharmacology Mentor is at your own risk.

Leave a Reply

Your email address will not be published. Required fields are marked *